Oral contraceptives for functional ovarian cysts

Grimes, David A.; Jones, LaShawn B.; Lopez, Laureen M; Schulz, Kenneth F.

doi:10.1002/14651858.cd006134.pub3

Cited by 9 publications

(6 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Premenopausal women with asymptomatic simple cysts smaller than 8cm on sonograms in whom the CA125 value was within the reference range can be monitored, with a repeat ultrasonographic examination in 8-12 weeks. Hormone treatment, comprising, as stated above, the use of the OCPs, is not helpful in resolving the cyst [10] .…”

Section: Management Of Ovarian Cystsmentioning

confidence: 99%

“…Nonetheless, meta-analyses had shown that there is no difference between OCP utilization and placebo in terms of management outcomes in ovarian cysts and that these masses ought to be monitored expectantly for numerous menstrual cycles. If a cystic mass does not resolve after this timeframe, it is unlikely to be a functional cyst, and further workup may be specified [10] .…”

Section: Management Of Ovarian Cystsmentioning

confidence: 99%

See 1 more Smart Citation

Causes and Management of Ovarian Cysts

Zahidy¹

2018

Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

An ovarian cyst is a sac filled with liquid or semiliquid material that arises in an ovary. While the discovery of an ovarian cyst causes considerable anxiety in women owing to fears of malignancy, the vast majority of these lesions are benign. Most patients with ovarian cysts are asymptomatic, with the cysts being discovered incidentally during ultrasonography or routine pelvic examination. Some cysts, however, may be associated with a range of symptoms, sometimes severe. Many patients with simple ovarian cysts found through ultrasonographic examination do not necessitate treatment. In a postmenopausal patient, a persistent simple cyst smaller than 10 cm in dimension in the presence of a normal CA125 value may be monitored with serial ultrasonographic examinations. When ovarian cysts are large, persistent, painful or have concerning radiographic or exam findings, surgery may be required, sometimes resulting in removal of the ovary. We conducted this review using a comprehensive search of MEDLINE, PubMed, EMBASE, Cochrane database of systematic reviews and Cochrane central register of controlled trials from

show abstract

Section: Management Of Ovarian Cystsmentioning

confidence: 99%

Section: Management Of Ovarian Cystsmentioning

confidence: 99%

Causes and Management of Ovarian Cysts

Zahidy¹

2018

Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

show abstract

“…There is an enormous variety of COCs on the market nowadays, differing in the type and dosage of progesterone and estrogen. COCs are recognized to have numerous non-contraceptive benefits, such as: pelvic pain relief in patients affected by endometriosis; treatment of PCO-related signs (acne and hirsutism); reduction of dysmenorrhea, menorrhagia, and consequently iron deficiency anemia; reduction of the risk of ovarian, colorectal, and endometrial cancer; reduction in the risk of benign breast disease; and reduction of ovary cysts [ 38 , 39 , 40 , 41 , 42 ]. However, hepatic diseases are a contraindication for the use of COCs, and, therefore, they cannot be administered in patients affected by ADPKD with hepatic involvement [ 30 ].…”

Section: Possible Therapeutic Strategies For Adpkd Patientsmentioning

confidence: 99%

Role of Female Sex Hormones in ADPKD Progression and a Personalized Approach to Contraception and Hormonal Therapy

Petrone,

Catania,

De Rosa

et al. 2024

JCM

View full text Add to dashboard Cite

This review navigates the intricate relationship between gender, hormonal influences, and the progression of autosomal dominant polycystic kidney disease (ADPKD), highlighting the limited literature on this crucial topic. The study explores the impact of female sex hormones on liver and renal manifestations, uncovering gender-specific differences in disease progression. Actually, hormonal therapy in women with ADPKD remains a challenging issue and is a source of concern regarding its potential impact on disease outcomes, particularly at the hepatic level. Notably, women with ADPKD exhibit a slower renal disease progression compared to men, attributed to hormonal dynamics. This review sheds light on the role of estrogen in regulating pathways of the renin–angiotensin–aldosterone system, revealing its complex interplay and implications for cardiovascular and renal health. Therapeutic considerations for fertile women with ADPKD, including contraception options, are discussed, emphasizing the necessity for personalized approaches. In the postmenopausal phase, the review evaluates the role of hormonal replacement therapy, considering its potential benefits and risks in the context of ADPKD. The review concludes by underscoring the imperative need for tailored treatment approaches for ADPKD patients, considering individual risks and benefits. The scarcity of literature underlines the call for further research to enhance our understanding of optimal hormonal therapies in the context of ADPKD, ultimately paving the way for innovative and personalized therapeutic interventions.

show abstract

“…Mithilfe der oben genannten Kriterien kann die Entscheidung bezüglich der weiteren notwendigen Maßnahmen leichter fallen. [25].…”

Section: Klinisches Managementunclassified